BERKELEY HEIGHTS, N.J. -- November 19, 2026 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) promoted Thomas Englese to chief commercial officer, effective immediately, in an announcement dated Sept. 8, 2026. CEO Seth Lederman calls it the company's first CCO appointment. Englese had held the title of executive vice president, commercial operations, since September 2024, which works out to two years.
Englese keeps three marketed products across two indications
He continues to direct sales, marketing, market access and commercial operations for three products. TONMYA (cyclobenzaprine HCl sublingual tablets) is for fibromyalgia in adults. Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray) are both for acute migraine in adults.
The release describes no change in scope. What changes is the title: the commercial organization for all three products now sits under a named C-suite officer.
Tonix says Englese's work since 2024 covered the go-to-market strategy and U.S. launch of TONMYA, with growth in sales, managed care and patient access. The company describes TONMYA as the first fibromyalgia treatment in more than 15 years. Englese said launch priorities remain "expanding access, growing patients and prescribers, and increasing sales." He cited an "encouraging start" and encouraging trends in launch key performance indicators. The company did not disclose TONMYA sales, prescriber counts or any other launch figure.
Englese has held the CCO title at two earlier employers
Before Tonix, Englese was chief commercial officer of Tris Pharmaceuticals, where he was responsible for the ADHD global brand business. He also held the title at Aziyo, where he ran the cardiac and soft tissue business and served on the initial public offering leadership team. Tonix is the third company at which he holds the CCO title, by our count.
At Mallinckrodt plc, formerly Ikaria Inc., he was senior vice president and general manager of North America Hospital Therapies, vice president and general manager of Global Critical Care, and vice president of Customer Operations. Earlier roles were at Baxter Healthcare International, as senior director of business operations, global analytics, and as a finance manager. He also held positions at Pfizer and Wells Fargo. He holds an MBA in finance from Pennsylvania State University and a B.S. in marketing from Villanova University.
Englese says the next phase is to expand the TONMYA launch to new healthcare providers and more deeply to current prescribers.